tiprankstipranks
Advertisement
Advertisement
Neumora Ends Navacaprant After Phase 3 Trial Failure
PremiumCompany AnnouncementsNeumora Ends Navacaprant After Phase 3 Trial Failure
1M ago
Neumora Therapeutics announces KOASTAL studies miss primary endpoint
Premium
The Fly
Neumora Therapeutics announces KOASTAL studies miss primary endpoint
1M ago
Neumora Shareholders Approve Directors, Auditor and Executive Pay
Premium
Company Announcements
Neumora Shareholders Approve Directors, Auditor and Executive Pay
2M ago
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
PremiumRatingsAnalyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
3M ago
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
Premium
The Fly
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
3M ago
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
Premium
Ratings
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
3M ago
Options Volatility and Implied Earnings Moves Today, March 30, 2026
PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, March 30, 2026
4M ago
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
Premium
The Fly
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
4M ago
NMRA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
NMRA Earnings this Week: How Will it Perform?
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100